Olema Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Olema Pharmaceuticals, Inc. on November 19, 2025. The report details a material event occurring on November 18, 2025, regarding a follow-on public offering of the company's common stock.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margins, or debt metrics. The primary financial data relates to the proposed capital raise:
- Shares Offered: 10,000,000 shares of Common Stock.
- Offering Price: $19.00 per share.
- Gross Proceeds: Approximately $190.0 million (before underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 1,500,000 additional shares.
- Expected Closing Date: November 20, 2025.
Material Changes
The material change reported is the execution of an underwriting agreement with TD Securities (USA) LLC to raise capital. This represents a significant increase in the company's equity capital pending the closing of the transaction. No comparative financial period data is included in this specific filing.
Outlook, Risks, and Contingencies
The closing of the offering is subject to the satisfaction of customary closing conditions. The filing includes standard forward-looking statements regarding the completion of the offering and expected proceeds, noting that actual results may differ materially due to risks and uncertainties. These risks are referenced as being detailed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $190.0 million gross proceeds.
- Confirm whether the underwriters exercise the option to purchase the additional 1,500,000 shares.
- Review the Form 10-Q for the quarter ended June 30, 2025, for detailed risk factors and current liquidity status.
- Check the final prospectus supplement for the exact amount of underwriting discounts and commissions to determine net proceeds.